Acanthamoeba Keratitis Clinical Trial
Official title:
Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis
Verified date | August 2023 |
Source | SIFI SpA |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prospective randomized study to evaluate the efficacy, safety and tolerability of 0.08% polihexanide (PHMB) eye drops in patients affected by acanthamoeba keratitis. 130 subjects were assigned to one of the following 2 treatment groups: Group 1: 0.08% polihexanide (PHMB) + placebo Group 2: 0.02% polihexanide (PHMB) + 0.1% propamidine
Status | Completed |
Enrollment | 135 |
Est. completion date | March 30, 2022 |
Est. primary completion date | June 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 13 Years and older |
Eligibility | Inclusion Criteria: 1. willing to give informed consent 2. man or woman of any race and =12 years of age 3. able to understand and willing to comply with study procedures, restrictions and requirements 4. Clinical findings consistent with Acanthamoeba keratitis 5. Confocal microscopy findings consistent with Acanthamoeba keratitis 6. The following previous treatments for Acanthamoeba keratitis are eligible: antibiotics, antiviral and antifungal drugs, antiinflammatory drugs 7. Females of childbearing potential will be included if they are either sexually inactive or using one highly effective contraceptive 8. Females of childbearing potential agree to remain sexually inactive or to keep the same birth control method for at least 28 days following the last study drug dose 9. A female of non-childbearing potential must have undergone one sterilization procedures at least 6 months prior to the first study drug dose 10. A non-vasectomized male subject agrees to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study drug and the female partner agrees to comply with inclusion 7 or 8. For a vasectomized male who has had his vasectomy 6 months or more prior to study start, it is required that they use a condom during sexual intercourse. A male who has been vasectomized less than 6 months prior to study start must follow the same restrictions as a non-vasectomized male. 11. If male, they must agree not to donate sperm from the first study drug dose until 90 days after dosing Exclusion Criteria: 1. Subject with documented history and/or clinical signs of concomitant presence of an ocular infection caused by viruses (herpes simplex virus [HSV]) or fungi. 2. Subject treated with drugs having effects on Acanthamoeba cysts prior to study entry, including biguanides (PHMB, chlorhexidine) and diamidines (propamidine, hexamidine). 3. Subjects requiring systemic immunosuppression for Acanthamoeba associated scleritis. 4. Subjects requiring urgent surgical intervention for advanced Acanthamoeba keratitis in either eye (e.g., for advanced corneal thinning/melting etc.). 5. Subject with known or suspected allergy to biguanides, diamidines or intolerance to any other ingredient of the investigational treatments. 6. Subject affected by immunodeficiency diseases or taking systemic immunosuppressive therapy. 7. Subject with a major systemic disease or other illness that would, in the opinion of the investigator, compromise subject's safety or interfere with the collection or interpretation of study results. 8. If female, pregnancy, planned pregnancy, or breast-feeding 9. Subject is participating in another interventional clinical study with an experimental or unapproved/unlicensed therapy or has participated in another interventional clinical study within 4 weeks prior to this study. |
Country | Name | City | State |
---|---|---|---|
Italy | San Raffaele Hospital | Milano | |
Italy | San Giovanni and Paolo Hospital | Venice | |
Poland | University Clinical Center Medical University of Silesia | Katowice | |
United Kingdom | Moorfields Hospital | London | |
United Kingdom | Manchester Royal Eye Hospital | Manchester | |
United Kingdom | University Hospital Southampton | Southampton |
Lead Sponsor | Collaborator |
---|---|
SIFI SpA |
Italy, Poland, United Kingdom,
Papa V, Rama P, Radford C, Minassian DC, Dart JKG. Acanthamoeba keratitis therapy: time to cure and visual outcome analysis for different antiamoebic therapies in 227 cases. Br J Ophthalmol. 2020 Apr;104(4):575-581. doi: 10.1136/bjophthalmol-2019-314485. Epub 2019 Aug 10. — View Citation
Papa V, van der Meulen I, Rottey S, Sallet G, Overweel J, Asero N, Minassian DC, Dart JKG. Safety and tolerability of topical polyhexamethylene biguanide: a randomised clinical trial in healthy adult volunteers. Br J Ophthalmol. 2022 Feb;106(2):190-196. doi: 10.1136/bjophthalmol-2020-317848. Epub 2020 Nov 25. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical Resolution Rate | Percentage of patients cured 30 days after discontinuing all study therapies, within 12 months of randomization | 12 months | |
Secondary | Time to Cure | Time needed to reach a clinical resolution | maximum 12 months | |
Secondary | Visual Acuity | Final visual acuity (best corrected) | maximum 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02506257 -
Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06332703 -
Acanthamoeba and Artificial Intelligence
|
||
Enrolling by invitation |
NCT03461978 -
Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures
|
N/A | |
Recruiting |
NCT02763605 -
Retrospective Study of Acanthamoebic Keratitis During the Past 10 Years
|
N/A | |
Active, not recruiting |
NCT03484507 -
Parasitic Ulcer Treatment Trial Pilot
|
Phase 2 | |
Active, not recruiting |
NCT05110001 -
Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
|
Phase 3 | |
Not yet recruiting |
NCT06213649 -
Parasitic Ulcer Treatment Trial
|
Phase 3 |